Shares of Parexel International Corp. (NASDAQ:PRXL) traded down 2.7% during trading on Monday . The company traded as low as $63.69 and last traded at $64.12, with a volume of 377,460 shares traded. The stock had previously closed at $65.92.

A number of analysts recently commented on the company. KeyCorp reiterated a “hold” rating on shares of Parexel International Corp. in a report on Sunday, May 22nd. Evercore ISI upgraded Parexel International Corp. from a “hold” rating to a “buy” rating in a report on Wednesday, June 1st. Zacks Investment Research lowered Parexel International Corp. from a “hold” rating to a “sell” rating in a report on Thursday, June 30th. Credit Suisse Group AG assumed coverage on Parexel International Corp. in a report on Monday, June 20th. They set an “outperform” rating and a $75.00 price target on the stock. They noted that the move was a valuation call. Finally, William Blair lowered Parexel International Corp. from an “outperform” rating to a “market perform” rating in a report on Monday. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $70.19.

The company has a market capitalization of $3.39 billion and a P/E ratio of 24.01. The firm’s 50-day moving average is $62.07 and its 200 day moving average is $62.06.

Parexel International Corp. (NASDAQ:PRXL) last posted its quarterly earnings results on Wednesday, April 27th. The company reported $0.89 earnings per share for the quarter, missing the consensus estimate of $0.90 by $0.01. The company earned $527.10 million during the quarter, compared to the consensus estimate of $523.16 million. The firm’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.66 EPS. On average, equities analysts anticipate that Parexel International Corp. will post $3.42 EPS for the current year.

In related news, Director Eduard E. Holdener sold 700 shares of the company’s stock in a transaction that occurred on Thursday, June 2nd. The stock was sold at an average price of $62.98, for a total value of $44,086.00. Following the sale, the director now owns 12,471 shares in the company, valued at approximately $785,423.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Ulf I. Schneider sold 6,000 shares of the company’s stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $60.01, for a total value of $360,060.00. Following the completion of the sale, the senior vice president now owns 33,530 shares in the company, valued at approximately $2,012,135.30. The disclosure for this sale can be found here.

Other institutional investors have added to or reduced their stakes in the company. ProShare Advisors LLC boosted its position in Parexel International Corp. by 27.1% in the fourth quarter. ProShare Advisors LLC now owns 14,931 shares of the company’s stock valued at $1,017,000 after buying an additional 3,187 shares during the period. GSA Capital Partners LLP boosted its position in Parexel International Corp. by 59.9% in the fourth quarter. GSA Capital Partners LLP now owns 15,232 shares of the company’s stock valued at $1,038,000 after buying an additional 5,709 shares during the period. Marshall Wace LLP acquired a new position in Parexel International Corp. during the fourth quarter valued at about $1,334,000. Bank of Montreal Can boosted its position in Parexel International Corp. by 25.8% in the fourth quarter. Bank of Montreal Can now owns 21,466 shares of the company’s stock valued at $1,462,000 after buying an additional 4,404 shares during the period. Finally, First Trust Advisors LP boosted its position in Parexel International Corp. by 1.1% in the fourth quarter. First Trust Advisors LP now owns 21,598 shares of the company’s stock valued at $1,471,000 after buying an additional 227 shares during the period.

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company, which provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and advanced technology products and services to the pharmaceutical, biotechnology and medical device industries across the world.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.